Real-World Evidence-Current Developments and Perspectives.

Area of Science:

• Health Economics and Outcomes Research
• Regulatory Science
• Data Science in Healthcare

Background:

• Real-world evidence (RWE) is increasingly utilized in early benefit assessments for medicinal drugs.
• The COVID-19 pandemic highlighted RWE's potential to expedite approval processes, similar to vaccine research.
• Diverse definitions of RWE indicate its evolving and dynamic nature in the scientific landscape.

Purpose of the Study:

• To review current developments and guidelines for real-world evidence (RWE) in the U.S. and Europe over the past decade.
• To assess the growing acceptance and importance of RWE in evaluating and accelerating new therapies.
• To identify gaps and the need for further guidance and a consented definition for RWE implementation.

Main Methods:

• Literature review of RWE developments and guidelines.
• Analysis of RWE inclusion in regulatory approval procedures.
• Exploration of various data sources contributing to RWE.

Main Results:

• RWE is actively incorporated into regulatory approval processes, demonstrating its acceptance.
• Data sources for RWE are diverse, including electronic health records, claims, patient-generated data, and registries.
• Regulatory authorities are increasingly using RWE for drug evaluation and approval.

Conclusions:

• Real-world evidence (RWE) plays a significant role in drug assessment and approval.
• Further standardization, a unified definition, and more guidance are essential for broader RWE implementation.
• Continued research and development are necessary to fully leverage RWE's potential in healthcare.